Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Novo Nordisk to acquire Cardior Pharmaceuticals
The take-over agreement includes Cardior’s lead compound CDR132L, currently in Phase II clinical development for the treatment of heart failure....
Innate immunity merger raises €75m
Dutch Oxitope and Norwegian Arxx announced their merger to form Calluna Pharma Inc with the goal to develop therapies for inflammatory and fibrotic...
Relation Therapeutics Ltd bags US$35m in seed financing.
The latest financing round of generative AI drug discovery company Relation Therapeutics was led by DCVC and co-led by NVIDIA's venture arm,...
Gene therapy supplier MIP Discovery closes £7M Series A financing
The £7m Series A financing of British gene therapy vector specialist MIP Discovery Ltd was led by lMercia Ventures.Existing investor Calculus Capital...
EU parliament backs deregulation of New Genome Techniques
With the MEPs' approval of the amendments to the European Commission's draft legislation, the way is now clear for a regulation that distinguishes...
Genmab broadens ADC pipeline with $1.8bn acquisition of ProfoundBio
The acquisition will give Genmab access to ProfoundBio's portfolio of antibody-drug conjugates (ADCs), three of which are in clinical trials. The...